HRP20140716T1 - Analozi oksitocina - Google Patents
Analozi oksitocina Download PDFInfo
- Publication number
- HRP20140716T1 HRP20140716T1 HRP20140716AT HRP20140716T HRP20140716T1 HR P20140716 T1 HRP20140716 T1 HR P20140716T1 HR P20140716A T HRP20140716A T HR P20140716AT HR P20140716 T HRP20140716 T HR P20140716T HR P20140716 T1 HRP20140716 T1 HR P20140716T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- image
- pain
- conditions
- connection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Gynecology & Obstetrics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4097308P | 2008-03-31 | 2008-03-31 | |
| EP08251739 | 2008-05-19 | ||
| PCT/IB2009/005351 WO2009122285A1 (en) | 2008-03-31 | 2009-03-30 | Oxitocin analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140716T1 true HRP20140716T1 (hr) | 2014-08-29 |
Family
ID=39722695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140716AT HRP20140716T1 (hr) | 2008-03-31 | 2009-03-30 | Analozi oksitocina |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8673841B2 (https=) |
| EP (2) | EP2260053B1 (https=) |
| JP (1) | JP5539310B2 (https=) |
| KR (1) | KR101558404B1 (https=) |
| CN (1) | CN101983205B (https=) |
| AU (1) | AU2009233429B2 (https=) |
| BR (1) | BRPI0910345B1 (https=) |
| CA (1) | CA2718148C (https=) |
| DK (1) | DK2260053T3 (https=) |
| ES (1) | ES2488992T3 (https=) |
| HR (1) | HRP20140716T1 (https=) |
| IL (1) | IL208039A (https=) |
| MX (1) | MX2010010743A (https=) |
| NZ (1) | NZ587817A (https=) |
| PL (1) | PL2260053T3 (https=) |
| PT (1) | PT2260053E (https=) |
| RU (1) | RU2496788C2 (https=) |
| SI (1) | SI2260053T1 (https=) |
| WO (1) | WO2009122285A1 (https=) |
| ZA (1) | ZA201006733B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2575853B1 (en) | 2010-05-25 | 2016-08-24 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| EP2935312B1 (en) | 2012-12-21 | 2018-08-08 | F.Hoffmann-La Roche Ag | Peptides as oxytocin agonists |
| AU2015270723A1 (en) * | 2014-06-03 | 2016-11-17 | F. Hoffmann-La Roche Ag | Peptides as oxytocin agonists |
| CR20160562A (es) * | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| ES2970059T3 (es) | 2014-09-19 | 2024-05-24 | Ferring Bv | Método de tratamiento del síndrome de Prader-Willi |
| CN106084015B (zh) * | 2016-08-25 | 2020-01-31 | 成都圣诺生物制药有限公司 | 一种合成卡贝缩宫素的方法 |
| US20190135859A1 (en) | 2017-08-11 | 2019-05-09 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| BR112020001832A2 (pt) * | 2017-08-11 | 2020-07-28 | Ferring B.V. | método de produção de uma composição farmacêuti-ca |
| CN107628975B (zh) * | 2017-09-17 | 2019-10-29 | 贵州医科大学 | 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用 |
| EP3852724A4 (en) | 2018-09-20 | 2022-07-06 | Levo Therapeutics, Inc. | CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE |
| TW202031283A (zh) | 2018-09-20 | 2020-09-01 | 馬克 Ｃ 曼寧 | 穩定卡貝縮宮素鼻內製劑 |
| JP7390031B2 (ja) * | 2018-12-27 | 2023-12-01 | 国立大学法人金沢大学 | オキシトシン誘導体及びその使用 |
| JP2023500763A (ja) * | 2019-11-04 | 2023-01-11 | フェリング ベスローテン フェンノートシャップ | 泌乳の改善のためのメロトシンの鼻腔内投与 |
| WO2022026463A1 (en) * | 2020-07-27 | 2022-02-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Oxytocin analogues and methods for using the same |
| ES3010259T3 (en) | 2021-03-26 | 2025-04-01 | Ot4B | Treatment of dysphagia |
| WO2024044633A2 (en) * | 2022-08-23 | 2024-02-29 | Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) | Oxytocin derivatives and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9604341D0 (sv) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| EP1480998B1 (en) * | 2002-02-27 | 2006-11-22 | Ferring BV | Intermediates and methods for making heptapeptide oxytocin analogues |
-
2009
- 2009-03-30 EP EP09727031.8A patent/EP2260053B1/en active Active
- 2009-03-30 AU AU2009233429A patent/AU2009233429B2/en active Active
- 2009-03-30 PT PT97270318T patent/PT2260053E/pt unknown
- 2009-03-30 JP JP2011502454A patent/JP5539310B2/ja active Active
- 2009-03-30 SI SI200930966T patent/SI2260053T1/sl unknown
- 2009-03-30 DK DK09727031.8T patent/DK2260053T3/da active
- 2009-03-30 KR KR1020107024207A patent/KR101558404B1/ko active Active
- 2009-03-30 CN CN200980111919.5A patent/CN101983205B/zh active Active
- 2009-03-30 HR HRP20140716AT patent/HRP20140716T1/hr unknown
- 2009-03-30 ES ES09727031.8T patent/ES2488992T3/es active Active
- 2009-03-30 NZ NZ587817A patent/NZ587817A/en unknown
- 2009-03-30 US US12/933,858 patent/US8673841B2/en active Active
- 2009-03-30 MX MX2010010743A patent/MX2010010743A/es active IP Right Grant
- 2009-03-30 PL PL09727031T patent/PL2260053T3/pl unknown
- 2009-03-30 EP EP13156710.9A patent/EP2626364A1/en not_active Withdrawn
- 2009-03-30 WO PCT/IB2009/005351 patent/WO2009122285A1/en not_active Ceased
- 2009-03-30 RU RU2010139634/04A patent/RU2496788C2/ru active
- 2009-03-30 CA CA2718148A patent/CA2718148C/en active Active
- 2009-03-30 BR BRPI0910345-7A patent/BRPI0910345B1/pt active IP Right Grant
-
2010
- 2010-09-07 IL IL208039A patent/IL208039A/en active IP Right Grant
- 2010-09-20 ZA ZA2010/06733A patent/ZA201006733B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2718148C (en) | 2017-11-07 |
| NZ587817A (en) | 2012-05-25 |
| ES2488992T3 (es) | 2014-09-01 |
| IL208039A0 (en) | 2010-12-30 |
| HK1146064A1 (en) | 2011-05-13 |
| MX2010010743A (es) | 2010-11-04 |
| US8673841B2 (en) | 2014-03-18 |
| BRPI0910345B1 (pt) | 2021-08-17 |
| US20110044905A1 (en) | 2011-02-24 |
| EP2260053A1 (en) | 2010-12-15 |
| CN101983205B (zh) | 2015-08-19 |
| SI2260053T1 (sl) | 2014-08-29 |
| KR101558404B1 (ko) | 2015-10-08 |
| BRPI0910345A2 (pt) | 2015-10-06 |
| CN101983205A (zh) | 2011-03-02 |
| DK2260053T3 (da) | 2014-06-23 |
| RU2010139634A (ru) | 2012-05-10 |
| AU2009233429B2 (en) | 2014-02-13 |
| WO2009122285A8 (en) | 2009-12-10 |
| JP2011516460A (ja) | 2011-05-26 |
| EP2260053B1 (en) | 2014-05-14 |
| AU2009233429A1 (en) | 2009-10-08 |
| RU2496788C2 (ru) | 2013-10-27 |
| JP5539310B2 (ja) | 2014-07-02 |
| ZA201006733B (en) | 2011-06-29 |
| EP2626364A1 (en) | 2013-08-14 |
| IL208039A (en) | 2016-03-31 |
| PL2260053T3 (pl) | 2014-11-28 |
| KR20110005705A (ko) | 2011-01-18 |
| PT2260053E (pt) | 2014-08-29 |
| CA2718148A1 (en) | 2009-10-08 |
| WO2009122285A1 (en) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140716T1 (hr) | Analozi oksitocina | |
| JP2013543492A5 (https=) | ||
| RU2016143751A (ru) | Фармацевтическая композиция | |
| JP2019501108A (ja) | 粘膜炎症を抑制するためのイガイ接着タンパク質生成物及びその使用 | |
| US20160136231A1 (en) | Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions | |
| JP2011516460A5 (https=) | ||
| CL2017000830A1 (es) | Formulación estable que comprende un azúcar no reductora, un anticuerpo anti-s4b7 y al menos un aminoácido libre; un método para preparar dicha formulación; uso de dicha formulación para tratar una enfermedad inflamatoria del intestino. | |
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| NZ602538A (en) | Thermogelling anaesthetic compositions | |
| FI3634419T3 (fi) | Gonadotropiinia vapauttavan hormonin antagonistin käsittävä annostusohjelma kohdun myoomien hoitamiseksi ja kuukautisten aiheuttaman verenhukan vähentämiseksi | |
| JP2011225596A5 (https=) | ||
| AU2020202835B2 (en) | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound | |
| RU2011134033A (ru) | Лекарственная форма для чресслизистого перорального введения анальгетических и/или антиспазматических молекул | |
| KR20220119051A (ko) | 신규한 다기능성 올리고펩타이드 | |
| JP2018528259A5 (https=) | ||
| US20230233506A1 (en) | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker | |
| HK1203394A1 (en) | Ghrelin receptor agonists for the treatment of achlorhydria | |
| RU2017114677A (ru) | Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество | |
| RU2018125252A (ru) | Синергическая комбинация пирролидонкарбоновой кислоты и/или ее солей и гиалуроновой кислоты и/или ее солей для применения в лечении и/или профилактике сухости и раздражения слизистых оболочек, и связанные фармацевтические композиции | |
| CN101642467A (zh) | 长效消毒膏 | |
| ES2641143T3 (es) | Una composición farmacéutica que comprende palmitoiletanolamida y citidina-difosfocolina | |
| JP2007291073A (ja) | 痔疾用噴霧製剤 | |
| WO2025087269A1 (en) | New short-chain peptides and derivatives thereof | |
| ES2363539T3 (es) | Composición farmacéutica para el tratamiento de la xerostomía. | |
| RU2249448C2 (ru) | Суппозитории с дибунолом и экстрактом прополиса для лечения гинекологических воспалительных заболеваний |